Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or >5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study

Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 11):8-9.
No abstract available